I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 2023-11-01 20:00
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 2023-10-16 20:00
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 2023-10-10 20:00
I-Mab Announces Upcoming Participation at September Conferences 2023-09-05 20:00
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates 2023-08-17 18:00
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 2023-08-08 20:00
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC 2023-07-05 20:00
I-Mab Announces the Appointment of Raj Kannan as CEO 2023-06-22 20:00
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 2023-05-26 05:01
I-MAB Filed 2022 Annual Report on Form 20-F 2023-05-01 20:00
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 2023-04-26 21:16
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon 2023-04-25 13:46
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China 2023-04-24 21:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 2023-03-31 18:30
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 2023-03-20 20:00
MSCI ESG Updated I-Mab to "A" Rating 2023-03-07 21:02
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 2022-11-03 21:01
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome 2022-09-13 20:00
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 2022-09-10 21:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 2022-08-30 18:00
1 2 3 4 5 9